Myasthenia gravis: Recommendations for clinical research standards

Neurology

Volumn 55, Issue 1, 2000, Pages 16-23

  Jaretzki III, A ^a,b   Barohn, R J ^c   Ernstoff, R M ^d   Kaminski, H J ^h   Keesey, J C ^e   Penn, A S ^f   Sanders, D B ^g  

^a Myasthenia Gravis Found Amer Inc   (United States)

^b New York Presbyterian Hospital Columbia University Medical Center   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d WILLIAM BEAUMONT HOSPITAL   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; PREDNISONE;

CLINICAL RESEARCH; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE SEVERITY; HUMAN; MYASTHENIA GRAVIS; PLASMAPHERESIS; PRIORITY JOURNAL; RATING SCALE; REVIEW;

EID: 0034641222     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.55.1.16     Document Type: Review

References (51)

1. Osserman KE. Clinical aspects. In: Osserman KE, ed. Myasmyasthenia thenia gravis. New York, NY: Grune & Stratton, 1958:79-80.
2. Barohn RJ, Mcintire D, Herbelin L, Wolfe GI, Nations S, Bryan W. Reliability testing of the quantitative myasthenia gravis score. Ann NY Acad Sci 1998;841:769-772.
3. Besinger UA, Toyka KV, Heininger K, et al. Long-term correlation of clinical course and acetylcholine receptor antibody in patients with myasthenia gravis. Ann NY Acad Sci 1981;377: 812-815.
4. Besinger UA, Toyka KV, Homberg M, Heininger K, Hohlfeld R, Fateh-Moghadam A. Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology 1983;33:1316-1321.
5. Hohlfeld R, Toyka KV, Besinger UA, Gerhold B, Heininger K. Myasthenia gravis: reactivation of clinical disease and of auto-immune factors after discontinuation of long-term azathioprine. Ann Neurol 1985;17:238-242.
6. Tindall RSA, Rollins JA, Phillips JT, et al. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 1987;316:719-724.
7. Barohn RJ. How to administer the quantitative myasthenia test. Video. 1996. Myasthenia Gravis Foundation of America, Inc., 123 West Madison, Suite 800, Chicago, IL 60602; e-mail: myastheniagravis@msn.com
8. Palace J. Azothiaprene vs prednisone - clinical trial. Neurology 1998;50:1778-1783.
9. Weijnen FG, VanDerBilt A, Wokke JHJ, Wassenberg MWM, Oudenaarde I. Oral functions of patients with myasthenia gravis. Ann NY Acad Sci 1998;841:773-776.
10. Younger DS, Braun NMT, Jaretzki A III, Penn AS, Lovelace AE. Myasthenia gravis: determinants for independent ventilation after transsternal thymectomy. Neurology 1984;34:336-340.
11. Andrews PI, Massey JM, Howard JF, Sanders DB. Race, sex, and puberty influence onset, severity, and outcome in juvenile myasthenia gravis. Neurology 1994;44:1208-1214.
12. Compston DAS, Vincent A, Newsom-Davis J, Batchelor JR. Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain 1980;103:579-601.
13. Seybold ME. Thymectomy in childhood myasthenia gravis. Ann NY Acad Sci 1998;841:731-741.
14. Grody WW, Jobst S, Keesey JC, Herrmann C, Naeim F. Pathologic evaluation of thymic hyperplasia in myasthenia gravis and Lambert-Eaton myasthenic syndrome. Arch Pathol Lab Med 1986;110:843-846.
15. Berrih-Aknin S. The in vivo effects of corticosteroids on thymocyte subsets in myasthenia gravis. J Clin Immunol 1984;4: 92-97.
16. Bertho X. Phenotype and immunohistochemical analyses of the human thymus: evidence for an active thymus during adult life. Cell Immunol 1997;179:30-40.
17. Marino M, Muller-Hermelink HK. Thymoma and thymic carcinoma. Relation of thymoma epithelial cells to the cortical and medullary differentiation of the thymus. Virchows Arch A Pathol Anat Histopathol 1985;407:119-149.
18. Lewis JE, Wick MR, Bernd W, Scheithauer MD, Bernatz PE, Taylor WF. Thymoma. A clinicopathologic review. Cancer 1987;60:2727-2743.
19. Muller-Hermelink HK, Marx A, Geuder K, Kirschner T. The pathological basis of thymoma-associatred myasthenia gravis. Ann NY Acad Sci 1993;681:56-65.
20. Close PM, Kirschner T, Uys CJ, Muller-Hermelink HK. Reproducibility of a histiogenic classification of thymic epithelial tumours. Histopathology 1995;26:339-343.
21. Muller-Hermelink HK, Willisch A, Schultz A, Marx A. Characterization of the human thymic microenvironment: lympho-epithelial interaction in normal thymus and thymoma. Arch Histol Cytol 1997;60:9-28.
22. Blumberg D, Burt ME, Bains MS, et al. Thymic carcinoma: current staging does not predict prognosis. J Thorac Cardiovasc Surg 1998;115:303-309.
23. Fukai I, Masaoka A, Fujii Y, et al. Thymic neuroendocrine tumor (thymic carcinoid): a clinicopathologic study. Ann Thorac Surg 1999;67:208-211.
24. Wick MR, Ritter JH. Thymic neuroendocrine tumors: a commentary with current perspectives on neuroendocrine neoplasia. Ann Thorac Surg 1999;67:7-9.
25. Kark AE, Kirschner PA. Total thymectomy by the transcervical approach. Br J Surg 1971;56:321-326.
26. Kark AE, Papatestas AE. Some anatomic features of the transcervical approach for thymectomy. Mt Sinai J Med 1971; 38:580-584.
27. Cooper J, Al-Jilaihawa A, Pearson F, Humphrey J, Humphrey HE. An improved technique to facilitate transcervical thymectomy for myasthenia gravis. Ann Thorac Surg 1988;45:242-247.
28. Bril V, Kojic S, Ilse W, Cooper J. Long-term clinical outcome after transcervical thymectomy for myasthenia gravis. Ann Thorac Surg 1998;65:1520-1522.
29. Durelli L, Maggi G, Casadio C, Ferri R, Rendine S, Bergamini L. Actuarial analysis of the occurrence of remission following thymectomy for myasthenia gravis in 400 patients. J Neurol Neurosurg Psychiatry 1991;54:406-411.
30. Klingen G, Johansson L, Westerholm CJ, Sundstroom C. Transcervical thymectomy with the aid of mediastinoscopy for myasthenia gravis: eight years' experience. Ann Thorac Surg 1977;23:342-347,
31. Yim APC, Kay RLC, Ho JKS. Video-assisted thoracoscopic thymectomy for myasthenia gravis. Chest 1995;108:1440-1443.
32. Mack MJ, Landreneau RD, Yim AP, Hazelrigg SR, Scruggs GR. Results of video-assisted thymectomy in patients with myasthenia gravis. J Thorac Cardiovasc Surg 1996;112:1352-1360.
33. Scelsi R, Ferro MT, Scelsi L, et al. Detection and morphology of thymic remnants after video-assisted thoracoscopic thymectomy (VATET) in patients with myasthenia gravis. Int Surg 1996;81:14-17.
34. Olanow CW, Wechsler AS. The surgical management in myasthenia gravis. In: Sabiston DC Jr, ed. Textbook of Surgery. 14th ed. Philadelphia, PA: WB Saunders, 1991:1801-1807.
35. Trastek VF. Thymectomy. In: Kaiser LR, Krin IL, Spray TL, eds. Mastery of cardiothoracic surgery. Philadelphia, PA: Lippincott-Raven, 1998:105-111.
36. LoCicero J III. The combined cervical and partial sternotomy approach for thymectomy. Chest Surg Clin North Am 1996;6: 85-93.
37. Granone P, Margaritora S, Cesario A, Galetta D. Thymectomy (transsternal) in myasthenia gravis via video assisted infra-mammary cosmetic incision. Eur J Cardiothorac Surg 1999; 15:861-863.
38. Mulder DG. Extended transsternal thymectomy. Chest Surg Clin North Am 1996;6:95-105.
39. Fischer JE, Grinvalski HT, Nussbaum MS, Sayers HK, Cole RE, Samaha FJ. Aggressive surgical approach for drug-free remission from myasthenia gravis. Ann Surg 1987;205:496-503.
40. Hatton P, Diehl J, Daly BDT, et al. Transsternal radical thymectomy for myasthenia gravis: a 15-year review. Ann Thorac Surg 1989;47:838-840.
41. Jaretzki A III, Wolff M. "Maximal" thymectomy for myasthenia gravis: surgical anatomy and operative technique. J Thorac Cardiovasc Surg 1988;96:711-716.
42. Bulkley GB, Bass KN, Stephenson R, et al. Extended cervicomediastinal thymectomy in the integrated management of myasthenia gravis. Ann Surg 1997;226:324-335.
43. Lennquist S, Andaker L, Lindvall B, Smeds S. Combined cervicothoracic approach in thymectomy for myasthenia gravis. Acta Chir Scand 1990;156:53-61.
44. Weinberg A, Gelijns A, Moskowitz A, Jaretzki A. Myasthenia gravis: outcomes analysis. 2000. Available at: http://www. neurology.org.
45. Miller RG, Rosenberg JA, Force APPT. Care of patient with ALS: report of the Quality Standards Subcommittee of the AAN. Neurology 1999;52:1311-1323.
46. Kirklin JW, Blackstone EH. Clinical studies with nonrandomly assigned treatment. In:Kirklin JW, Barrett-Boyes BG, eds. Cardiac surgery. 2nd ed. New York, NY: Churchill-Livingstone, 1993:269-270.
47. Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA 1996;276:637-639.
48. Schulz KF. The quest for unbiased research: randomized clinical trials and the CONSORT reporting guidelines. Ann Neurol 1997;41:569-573.
49. Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology 1999;52:1487-1489.
50. Jaeschke R, Guyatt GH. How to develop and validate a new quality of life instrument. In: Spilker B, ed. Quality of life assessments in clinical trials. New York, NY: Raven Press, 1990:47-57.
51. Kirklin JW, Vicinanza SS. Metadata and computer-based patient records. Ann Thorac Surg 1999;68:S23-S24.